Literature DB >> 3923025

Plasma GH responses to GHRH and insulin-induced hypoglycemia in man.

T Shibasaki, M Hotta, A Masuda, T Imaki, N Obara, H Demura, N Ling, K Shizume.   

Abstract

Changes in plasma GH levels in response to an intravenous bolus injection of 200 micrograms GHRH-44 or 0.1 U/kg body weight regular insulin were examined in normal men who were pre-treated with 200 micrograms GHRH-44 or 0.1 U/kg body weight regular insulin 120 min in advance. The prior bolus injection of GHRH-44 inhibited the plasma GH response to the subsequent administration of GHRH-44 whereas the plasma GH response to the subsequent injection of insulin was not influenced by the prior administration of GHRH-44. The prior administration of insulin attenuated the plasma GH response to the subsequently given GHRH-44. These results suggest that desensitization of GHRH receptors in somatotrophs and/or somatostatin hypersecretion induced by increase in plasma GH levels following the prior GHRH-44 administration may be involved in the mechanism by which the prior GHRH-44 administration or insulin-induced hypoglycemia suppressed plasma GH responses to the following GHRH-44 administration. Sudden suppression of somatostatin secretion, which causes rebound of GH secretion, may occur in insulin-induced hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923025     DOI: 10.1210/jcem-60-6-1265

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Secretion of growth hormone releasing hormone in obese children.

Authors:  S Loche; S Balzano; M Bozzola; A Moretta; S Pintus; A Faedda; A Muntoni; D Carta; C Pintor
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

2.  Growth hormone release during insulin tolerance, clonidine, arginine and growth hormone releasing hormone tests in short normal children and adolescents.

Authors:  L Cavallo; A Acquafredda; S Liuzzi; R Russo; C Zecchino; R Leuzzi; T Giobbe; L Piacente
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

3.  Role of growth hormone-releasing hormone on pentagastrin-induced growth hormone release in normal subjects.

Authors:  J F Garcia-Rojas; A Mangas; A Barba; J Millan; C Dieguez; E Zamora
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

Review 4.  Growth hormone cotreatment with gonadotropins in ovulation induction.

Authors:  P G Artini; A A de Micheroux; G D'Ambrogio
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

Review 5.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

6.  The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.

Authors:  M L Drent; H J Adèr; E A van der Veen
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

7.  Galanin infusion partially restores the blunted growth hormone responses to repeated growth hormone releasing hormone stimuli in normal adults.

Authors:  A Sartorio; A Spada; A Conti; G Grugni; F Morabito; G Faglia
Journal:  J Endocrinol Invest       Date:  1993-02       Impact factor: 4.256

8.  Study on the mechanism of abnormal growth hormone (GH) secretion in anorexia nervosa: no evidence of involvement of a low somatomedin-C level in the abnormal GH secretion.

Authors:  A Masuda; T Shibasaki; M Hotta; H Suematsu; K Shizume
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

Review 9.  GH/IGF-I axis in anorexia nervosa.

Authors:  L Gianotti; F Lanfranco; J Ramunni; S Destefanis; E Ghigo; E Arvat
Journal:  Eat Weight Disord       Date:  2002-06       Impact factor: 4.652

10.  A prospective study of hypothalamus pituitary function after cranial irradiation with or without radiosensitizing chemotherapy.

Authors:  T S Huang; S C Huang; M M Hsu
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.